Patient disposition in the SOC arm and axi-cel arm for subsequent 3L therapy. (A) SOC arm and (B) axi-cel arm. ∗Patients received axi-cel (n = 51); other autologous anti-CD19 CAR T-cell therapy (n = 10); unspecified CAR T-cell therapy (n = 3); anti-CD19/CD22 CAR T-cell therapy, allogeneic CRISPR-Cas9 engineered T cells, anti-CD22 CAR T-cell therapy, and natural killer-cell infusion (n = 1 each). ^†Patients may have received >1 3L regimen. Other 3L regimens included radiation (n = 4), nivolumab (clinical trial, n = 4), pembrolizumab (n = 2 [with n = 1 on clinical trial]), ipilimumab (clinical trial, n = 1), R-lenalidomide (n = 2), varlilumab (clinical trial, n = 2), oral dihydroorotate (clinical trial, n = 1), CPI-613 (clinical trial, n = 1), dexamethasone (n = 1), HDT-ASCT (n = 1), and allogeneic SCT (n = 1). For the patient under “other 3L regimens” classified as receiving allogeneic SCT, the patient received cyclophosphamide and fludarabine as lymphodepleting chemotherapy without any other chemoimmunotherapy prior to alloSCT; for this reason, the patient was not categorized into the 3L chemotherapy group. For the patient under “other 3L regimens” classified as received HDT-ASCT, the patient received nivolumab with ipilimumab (without any chemoimmunotherapy) before HDT-ASCT and, therefore, was not categorized into the 3L chemotherapy group. ^‡Among these 60 patients, only 1 received 3L polatuzumab vedotin plus bendamustine and rituximab. ^§Refers to SCT in any line. Three patients received allogeneic SCT after 3L axi-cel in the absence of progression. PD, progressive disease.